

References

- Abboud, S. and Haile, D.J, (2000):** A novel mammalian iron-regulated protein involved in intracellular iron metabolism. *J Biol Chem* 275:19906-12.
- Aboul Enein M, Nasr E and Ahmed A, (1986):** proposed Egyptian modification of FAB (FAB-E). *Egypt.j.hematol.* 11:121
- Alyea EP, Kim HT, Ho V, et al., (2006):** Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome". *Biol. Blood Marrow Transplant.* 12 (10): 1047–55.
- Andrews NC, (2004):** Anemia of inflammation: the cytokine-hepcidin link. *J. Clin. Invest;* 113(9): 1251-1253.
- Andrews, N.C. and Schmidt, PJ, (2007):** Iron homeostasis. *Annu Rev Physiol:* 69-85.
- Aplenc R, Alonzo TA, Gerbing RB, et al., (2006):** Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group. *Blood* 108 (1): 74-80.
- Arceci RJ, (2002):** Progress and controversies in the treatment of pediatric acute myelogenous leukemia. *Curr Opin Hematol* 9 (4): 353-60.
- Arvedson T C, Li H, Rose M, et al., (2008):** Evaluation of serum hepcidin concentrations in cancer and leukemia patients, *J Clin Oncol* 26: abstr 20581.
- Athale UH, Razzouk BI, Raimondi SC, et al., (2001):** Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. *Blood* 97 (12): 3727-32.
- Babitt J.L, Huang F.W, Wrighting D.M, et al., (2006):** Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. *Nat Genet* 38, 531-9.

- Balduzzi A, Valsecchi MG, Underzo C et al., (2005):** Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukemia in first complete remission: by genetic randomization in an international prospective study. *Lancet* 366(9486):635-42, Aug 20-26
- Barbarie D, Alonzo TA, Gerbing RB, et al., (2007):** Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961. *Blood* 109 (6): 2314-21.
- Baron F, Maris MB, Sandmaier BM, et al., (2005):** Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning". *J. Clin. Oncol.* 23 (9): 1993–2003.
- Bayele HK and Srai SK, (2009):** Regulatory variation in hepcidin expression as a heritable quantitative trait. *Biochem Biophys Res Commun*; 384(1):22-27.
- Bene M, Bernier M and Castoldi G, (2003):** Impact of immunophenotyping on management of acute leukemias. *Haematologica*; 84:1024.
- Bhakhri BK, Vaidya PC, Trehan A et al., (2012)** Iron deficiency anemia in children presenting with lymphoreticular malignancies *Pediatr Hematol Oncol.* 2012 Mar;29(2):148-53.
- Bhatia S and Neglia JP, (2006):** Epidemiology of childhood acute myelogenous leukemia, *J pediatric Hematol onco.* vol.25 pp 94-100.
- Birgegård G, Gascón P, and Ludwig H, (2006):** Evaluation of anaemia in patients with multiple myeloma and lymphoma: Findings of the European Cancer Anaemia Survey. *Eur J Haematol*;77:378-386.
- Bondi A, Valentino P, Daraio F, et al., (2005):** Hepatic expression of hemochromatosis genes in two mouse strains after phlebotomy and iron overload. *Haematologica* 90, 1161-7.
- Bosman DR, Winkler AS, Marsden JT et al., (2001):** Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. *Diabetes*

Care; 24:495-499.

Bostorm BC, Sensel MR and Sather HN, (2003): Dexamethasone versus prednisone daily oral versus weekly intravenous mercaptopurine for patients with standard risk acute lymphoblastic leukemia: a report from the Children Cancer Group. *Blood* 101 (10):3809.

Broxon EH, Dole M, Wong R et al., (2005): Portal hypertension develops in a subset of children with standard risk acute lymphoblastic leukemia treated with oral 6-thioguanine during maintenance therapy. *Pediatr Blood Cancer* 44(3):226-31.

Brumariu O, Miron I, Maimescu L et al., (2000): Osteoarticular changes in childhood leukemia, lymphoma and neuroblastoma. *Rev Med Chir Soc Med Nat Iasi*; 104(4):67-69.

Bruno B, Rotta M, Patriarca F, et al., (2007): A comparison of allografting with autografting for newly diagnosed myeloma". *N. Engl. J. Med.* 356 (11): 1110–20.

Bürger B, Zimmermann M, Mann G et al., (2003): Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. *J Clin Oncol* 21(2):184-8.

Burt RK, Loh Y, Pearce W et al., (2008): Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases *JAMA* 299 (8): 925–36.

Camaschella C and Silvestri L, (2008): New and old players in the hepcidin pathway. *Haematologica*; 93(10):1441-1444.

Campana D and Pui CH, (2004): Childhood Leukemia. In: Abeloff. MD, Armitage JO, Neiderhuber JE, Kastan MB, Mckana WG(editors). *Abeloff: Clinical Oncology, 3rd Edition.* Churchill Livingstone, Philadelphia; P: 2731-276.

- Cancer Treatment Centers of America, (2009):** Leukemia Information at: [www.cancer center .com/leukemia.cfm](http://www.cancercenter.com/leukemia.cfm).
- Canellos and George, (1997):** "The Role of Salvage Therapy in Malignant Lymphomas". *The Oncologist* 2 (3): 181–183.
- Carrol WL, Bhojwani D, Min DJ et al., (2003):** Pediatric acute lymphoblastic leukemia. *Hematology (Am Soc Hematol Educ Program)*:102-31
- Chan KW, (2002):** Acute lymphoblastic leukemia. *Curr Probl Pediatr Adolesc Health Care*. Feb; 32(2):40-9.
- Chang M, Raimondi SC, Ravindranath Y et al., (2000):** Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821. *Leukemia* 14 (7): 1201-7.
- Cheng PP, Sun ZZ, Jiang F et al.,(2012)**Hepcidin expression in patients with acute leukaemia. *Eur J Clin Invest*. 2012 May;42(5):517-25.
- Cheson BD, Bennett JM, Kopecky KJ et al., (2003):** Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. *J Clin Oncol* 21 (24): 4642-9.
- Childhood Acute Lymphoblastic Leukemia (PDQ®) (2005):** Treatment Health Professional Version from the US National Cancer Institute.
- Choi S.O, Cho Y.S, Kim H.L and Park J.W, (2007):** ROS mediate the hypoxic repression of the hepcidin gene by inhibiting C/EBPalpha and STAT-3. *Biochem Biophys Res Commun* 356, 312-7.
- Confer D and Robinett P, (2008):**The US National Marrow Donor Program role in unrelated donor haematopoietic stem cell transplantation. *Bone Marrow Transplant*; 42:S3–S5.
- Consetini R, Legitimo A and Rondelli R, (1998) :** Clinical relevance of CD10

- expression in childhood ALL, the Italian Association for Pediatric Hematology and Oncology. *Hematologica*. 83:967.
- Corazza F, Beguin Y, Bergmann P, et al., (1998):** Anemia in children with cancer is associated with decreased erythropoietic activity and not with inadequate erythropoietin production. *Blood*. 92:1793–1798.
- Coustan-Smith E, Sancho J and Hancock ML, (2002):** Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. *Blood* 100(7): 2399-402 .
- Creutzig U, Reinhardt D, Diekamp S et al., (2005):** AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. *Leukemia* 19 (8): 1355-60.
- Crist WM and Smithson WA,(2008):** The leukemias.In : Nelson textbook of pediatrics, 18th edition. (5th ed).
- Cutler C and Antin JH ,(2001);** "Peripheral blood stem cells for allogeneic transplantation: a review". *Stem Cells* 19 (2): 108–17. doi:10.1634/stemcells.19-2-108. PMID 11239165.
- De Botton S, Coiteux V, Chevret S, et al., (2004):** Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. *J Clin Oncol* 22 (8): 1404-12.
- De Domenico I, Ward DM and Kaplan J, (2007):** Hepcidin regulation: ironing out the details. *J. Clin. Invest*; 117(7): 1755-1758.
- Delaby C, Pilard N, Goncalves AS, et al., (2005a):** Presence of the iron exporter ferroportin at the plasma membrane of macrophages is enhanced by iron loading and down-regulated by hepcidin. *Blood* 106, 3979-84.
- Dickinson HO, (2005):** The cause of childhood leukemia.*BMJ*. Jun 4; 330(7503):1279-80.
- Donadieu C, Chu and Allerga CJ, (2000):** Antifolates. In: Chabner BA, Longo DL, eds: *Cancer chemotherapy and Biotherapy: Principles and practice*. Philadelphia: Lippincott-Raven, 109-148.

- Donovan A, Brownlie A, Zhou Y et al., (2000):** Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. *Nature* 403, 776-81.
- Donovan A, Lima CA, Pinkus JL, et al., (2005):** The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. *Cell Metab* 1 , 191-200.
- Du X, She E, Gelbart T, Truksa J et al., (2008):** The serine protease TMPRSS6 is required to sense iron deficiency. *Science*; 320(5879):1088-1092.
- El halwany A, Assan H ,Sharaky O et al.,(2005) :** serum level of vascular endothelial growth factors in children with ALL. MSc Thesis in pediatrics Ain shams university.
- El hennawy S, Mohammed I ,Attia I et al.,(2005) :**ferritin and creatinkinase in CSF of children with ALL.MSc Thesis in pediatrics Ain shams university.
- Elad S, Zadik Y, Hewson I, et al., (August 2010).** "A systematic review of viral infections associated with oral involvement in cancer patients: a spotlight on Herpesviridea". *Support Care Cancer* 18 (8): 993–1006.
- El-Alfy M, Ezaat W, Shalabi M et al., (2000):** Are siblings and first cousins of children with cancer at increased risk of cancer. *Egyptian Journal of Pediatrics*; 17(1&2): 233-241.
- Elattar I, Hassan N, Mounir M et al., (2006):** Cancer Statistics, NCI Egypt. 2002-2005.
- Eschbach JW, Egrie JC, Downing MR, et al., (1987):** Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. *N Engl J Med*. 316:73–78.
- Ezaat A,Soliman D and Abd-Allah S, (2011) :**risk of bacteremia in children with ALL and febrile neutopenia. MSc Thesis in pediatrics Benha university.

- Faquin WC, Schneider TJ and Goldberg MA, (1992)** :Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. *Blood*. 79:1987–1994.
- Ford AM, Pomo-de`oliveria MS, McCartly KP et al.,(2002)**: Monoclonal origin of concordant T-cell malignancy twins; *Blood*; 89:281.
- Frazer D.M, Inglis H.R, Wilkins S.J, et al.,(2004)**: Delayed hepcidin response explains the lag period in iron absorption following astimulus to increase erythropoiesis. *Gut* 53, 1509-15.
- Gadalla A, (1996)**: Profile of childhood cancer in the national cancer institute from 1975- 1994. M. SC. Thesis of Pediatrics, National cancer institute, cairo university.
- Gajjar A, Harrison PL, Sandlund J T et al.,(2000)** Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. *Blood*. 2000 Nov 15;96(10):3381-4.
- Ganz T, (2003)**: "Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation". *Blood* 102 (3): 783–8.
- Ganz T and Nemeth E,(2006)**. Iron imports. IV. Hepcidin and regulation of body iron metabolism. *Am J Physiol Gastro-intest Liver Physiol*; 290:199-203.
- Ganz T, Olbina G, Girelli D et al., (2008)**: Immunoassay for human serum hepcidin. *Blood* 112(10): 4292–4297.
- Gilham C, Peto J, Simpson J et al., (2005)**: UKCCS Investigators. Day care in infancy and risk of childhood acute lymphoblastic leukemia: findings from UK case control study.*BMJ*. Jan 4; 330(7503):1294.
- Glavel J, Goubin A, Auclerc MF, et al.,(2004)**: Incidence of childhood leukaemia.
- Gnana-Prakasam JP, Martin PM, Mysona BAet al., (2008)**: Hepcidin expression in mouse retina and its regulation via lipopolysaccharide/Toll-like receptor-4 pathway independent of Hfe. *Biochem J*; 411:79-88.

- Goldberg MA, Glass GA, Cunningham JM and Bunn HF.,(1987):** The regulated expression of erythropoietin by two human hepatoma cell lines. *Proc Natl Acad Sci U S A.* 84:7972–7976. .
- Gratwohl A, Baldomero H, Frauendorfer et al., (2008):** for the Joint Accreditation Committee of the International Society for Cellular Therapy ISCT and the European Group for Blood and Marrow Transplantation EBMT (JACIE) The EBMT activity survey 2006 on hematopoietic stem cell transplantation: focus on the use of cord blood products. *Bone Marrow Transplant.*;41:687–705.
- Greaves MF, (2002)** Etiology of acute Childhood leukaemia. *BMJ.*; 324(7332): 283–287.
- Greaves MF and Alexander FE,(2003):** An infectious etiology for acute lymphoblastic leukemia in children. *Leukemia*; 7(3):49.
- Greaves MF, Maia AT, Wiemels JL,et al.,(2003)** Leukemia in twins: lessons in natural history. *Blood* 102 (7): 2321-33,
- Han X and Bueso-Ramos CE, (2005):** Advances in the pathological diagnosis and biology of acute lymphoblastic leukemia. *Ann Diagn Pathol.* Aug; 9(4):239-57.
- Hann I, Vora A, Richards S, et al., (2000):** Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials. UK Medical Research Council's Working Party on Childhood Leukaemia. *Leukemia* 14 (3): 356-63.
- Hann IM, Webb DK, Gibson BE, et al., (2004):** MRC trials in childhood acute myeloid leukaemia. *Ann Hematol* 83 (Suppl 1): S108-12, 2004.
- Harrison CJ, Moorman AV, Barber KE, et al., (2005)** Interphase molecular cytogenetic screening for chromosomal abnormalities of prognostic significance

in childhood acute lymphoblastic leukaemia: a UK Cancer Cytogenetics Group Study. *Br J Haematol*; 129:520.

Harrison-Findik DD, (2009): Is the iron regulatory hormone hepcidin a risk factor for alcoholic liver disease. *World J Gastroenterol*; 15(10): 1186–1193.

Hasle H, Alonzo TA, Auvrignon A et al., (2007): Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. *Blood* 109 (11): 4641-7, 2007.

Hassab H, Abou Seif M and Farrahat N,(2002) : Comparison of MDR1 expression by lymphoblasts with Rh 123 functional activity by flowcytometry in children with acute lymphoblastic leukemia. *Alex J Pediatr*; 16(1):1.

Heerema NA, Nachman JB, Sather NH et al., (1999): Hyperploidy with less than 45 chromosomes confers adverse risk in children with acute lymphoblastic leukemia: a report from the Children Cancer Group. *Blood*; 94(12).1581-1586.

Heerema NA, Sather HN, Sensel MG et al., (2000): Prognostic impact of trisomies of chromosomes 10,17,5 Among Children with Acute Lymphoblastic Leukemia and High Hyperdiploidy(>50 chromosomes).*J Clin Oncol*;18(9):1876-1887.

Hillman RS, Finch CA ,Bomken S et al.,(1997) : Red Cell Manual. 7th Edition. Philadelphia, PA: FA Davis:190.

Hoelzer D, Gokbuget N, Ottmann O et al., (2002) : Acute lymphoblastic leukemia. *Hematology*; 1:162-192.

Hohaus s, Massini G, Giachelia M et al. , (2009).: Anemia in Hodgkin's Lymphoma: The Role of Interleukin-6 and Hepcidin, *Journal of clinical oncology*;28(15):2538-43.

Huang H, Constante M, Layoun A, and Santos M M, (2009) : “Contribution

- of STAT3 and SMAD4 pathways to the regulation of hepcidin by opposing stimuli,” *Blood*, vol. 113, no. 15, pp. 3593–3599,
- Hussein H, Sidhom I, Abou El Naga S and Zamzam M,(2004):** Survival and prognostic factors of acute lymphoblastic leukemia in children at the National Cancer Institute. Egypt .*Journal of the Pediatric hematology/oncology*vol.26 pp507-514.
- Ie Viseur C, Hotfilder M, Bomken S, et al., (2008):** In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. *Cancer Cell*; 14(1):47-58.
- Inamura J, Ikuta K, Jimbo J, et al., (2005):** Upregulation of hepcidin by interleukin-1beta in human hepatoma cell lines. *Hepatol Res* 33 ,198-205.
- Inskip PD, Harvey EB, Boice JD Jr, et al., (1991):** Incidence of childhood cancer in twins. *Cancer Causes Control* 2 (5): 315-24.
- Kawabata H, Tomosugi N, Kanda J, et al., (2007) :** “Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease,” *Haematologica*, vol. 92, no. 6, pp. 857–858,
- Kearney S. L, Nemeth E, Neufeld E. J, et al.,(2007),** “Urinary hepcidin in congenital chronic anemias,” *Pediatric Blood and Cancer*, vol. 48, no. 1, pp. 57–63.
- Kemna E. H. J. M, Tjalsma H, Podust V. N, and Swinkels D. W, (2007):** “Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications,” *Clinical Chemistry*, vol. 53, no. 4, pp. 620–628.
- Kemna EHJM, Willems HL, Wswinkels DW and Tjalsma H, (2008):** Hepcidin from discovery to differential diagnosis. *haematol*.11705 *haematol* January 1, 2008 vol. 93 no. 1 90-97.
- Klaus S, Arend M, Fourney P et al., (2005).** “Induction of erythropoiesis and iron utilization by the HIF prolyl hydroxylase inhibitor FG-4592,” *Journal*

- of the American Society of Nephrology, vol. 16, p. 49A,
- Kohler T, Leiblein S, Borchert S et al., (2003):** Absolute levels of MDR 1, MRP and BCL-2 mRNA and tumor remission in acute leukemia. *Leuk Lymphoma*; 9:44
- Krause A, Neitz, S, Magert H.J et al.,(2000):** LEAP-1, a novel highly disulfide- bonded human peptide, exhibits antimicrobial activity. *FEBS Lett* 480 ,147-50.
- Kroot J.J.C, Hendriks J.C.M, Laarakkers C.M.M, et al., (2009) :** “(Pre)analytical imprecision, between-subject variability, and daily variations in serum and urine hepcidin: implications for clinical studies,” *Analytical Biochemistry*, vol. 389, no. 2, pp. 124–129.
- Kulaksiz H, Fein E, Redecker P, Stremmel W, et al., (2008):** Express hepcidin, an iron-uptake regulatory peptide. *J endocrinol*; 197:241-249.
- Kwan ML, Buffler PA, Wiemel JL, and Selvin S, (2005):** Breastfeeding pattern and risk of childhood acute lymphoblastic leukemia. *Br J Cancer*. Aug 8; 93(3):379-84.
- Lancet A, (2000):** Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukemia: overview of 42 trials involving 12 000 randomized children. *Childhood ALL Collaborative Group*, 347(9018):1783-8.
- Lange BJ, Koblinsky N, Barnard DR, et al., (1998):** Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. *Blood* 91 (2): 608-15.
- Lange BJ, Gerbing RB, Feusner J, et al., (2005):** Mortality in overweight and underweight children with acute myeloid leukemia. *JAMA* 293 (2): 203-11.
- Lange BJ, Smith FO, Feusner J, et al., : (2008):** Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute

- myeloid leukemia: a report from the children's oncology group. *Blood* 111 (3): 1044-53.
- Lanzkowsky P, (2011):** Leukemia. In: *Manual Of Pediatric Hematology and Oncology*, 5th edition. PP315-411.
- Latunde-Dada G.O, Vulpe C.D, Anderson G.J, et al. ,(2004):** Tissue-specific changes in iron metabolism genes in mice following phenylhydrazine-induced haemolysis. *Biochim Biophys Acta* 1690 :169-76
- Le Clerc JM, Billett AL , Gelber RD, et al.,(2002):** Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01. *J Clin Oncol* 20(1):237-46.
- Lee P, Peng H, Gelbart T, et al. ,(2005a):** Regulation of hepcidin transcription by interleukin-1 and interleukin-6. *Proc Natl Acad Sci U S A* 102 : 1906-10.
- Lehrnbecher T, Zimmermann M, Reinhardt D, et al., (2007):** Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia. *Blood* 109 (3): 936-43.
- Leong WI and Lonnerdal B, (2004):** Hepcidin, the recently identified peptide that appears to regulate iron absorption. *J Nutr*; 134:1-4. *Leukemia* 2005;19(12):2030–42.
- Leung W, Hudson MM, Strickland DK, et al., (2000):** Late effects of treatment in survivors of childhood acute myeloid leukemia. *J Clin Oncol* 18 (18): 3273-9.
- Li H, Rose M. J, Tran L, et al., (2009) :** “Development of a method for the sensitive and quantitative determination of hepcidin in human serum using LC-MS/MS,” *Journal of Pharmacological and Toxicological Methods*, vol. 59, no. 3, pp. 171–180.
- LihtehWU,(2005):**Leukemias.<http://www.emedicine.com/med/topic.489.htm>.
- Linnet MS, Hatch EE, Kleieman RA, et al., (2004):** Residential exposure to magnetic fields and acute lymphoblastic leukemia in children. *N Engl J*

Med;337(1):1.

Littlewood T, and Mandelli F, (2002): The effects of anemia in hematologic malignancies: More than a symptom, *Seminars in Oncology*, Volume 29, Issue 3, Supplement 8, Pages 40-44.

Loeb DM and Arceci RJ, (2002): What is the optimal therapy for childhood AML? *Oncology (Huntingt)* 16 (8): 1057-66; discussion 1066, 1068-70.

Ludwig WD, Raghavachar A and Thiel E,(1994):. Immunophenotypic classification of acute lymphoblastic leukemia. *Bailliere's Clin. Hematol.* 7:235 .

M, Seifert M, et al. ,(2008). Autocrine formation of hepcidin induces iron retention in human monocytes. *Blood*, 111:2392–2399 .

Mahoney DH JR, Shuster JJ, Nitschke R, et al., (2000): Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia. *J Clin Oncol.*;18(6):1285-94.

Mangano JJ, Sherman J, Chang C et al., (2003): Elevated childhood cancer incidence proximate to U.S. nuclear power plants. *Arch Environ Health.* Feb; 58(2):74-82.

Marcucci G, MrÅzek K, Ruppert AS, et al., (2004): Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from Cancer and Leukemia Group B study 8461. *J Clin Oncol* 22 (12): 2410-8.

Margolin J and Poplack D, (2009): Acute lymphoblastic leukemia. In Pizzo P and Poplack D (eds): *Principles and Practice of Pediatric Oncology* (Fifth edition) New Yourk, Lippincott-Raven.

Maris MB, Sandmaier BM, et al., (2005). "Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning". *J. Clin. Oncol.* 23 (9): 1993–2003.

- Martin B, Taylor AMR, Metcalfe JA and Thick J, (1996):** Leukemia and lymphoma. *Blood*; 87:423
- McKie A.T, Marciani P, Rolfs A, et al. ,(2000).:** A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. *Mol Cell* 5 ,299-309.
- McNeil DE, Cote` TR, Clegg L, et al., (2002):** Update of incidence and trends in pediatric malignancies: acute lymphoblastic leukemia. *Blood* 88 (11): 4252-8 Mills PK, Zahm SH. Organophosphate pesticide residues in urine of monitoring of acute myeloid leukemia. *Leukemia* 19 (8): 1416-23
- Means RT, Krantz SB, Powelson J et al., (1996).** Inhibition of human erythroid colony-forming units by interferons alpha and beta: differing mechanisms despite shared receptor. *Exp Hematol.* 24:204–208
- Melis M. A, Cau M, Congiu R, et al., (2008).** “A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron,” *Haematologica*, vol. 93, no. 10, pp. 1473–1479,
- Miller CB, Jones RJ, Piantodosi S, et al.,(1990).q.** Decreased erythropoietin response in patients with the anemia of cancer. *N Engl J Med.* 322:1689–1692.
- Mills PK and Zahm SH,(2001)** Organophosphate pesticide residues in urine of and their children in Fresno County, California. *Am J Ind Med* 2001;40(5):571–7.
- Mistry AR, Pedersen EW, Solomon E, et al., (2003):** The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. *Blood Rev* 17 (2): 71-97.
- Mokhtar M,Tantawy A ,Afifi H et al.,(2010):**estimation of surviving expression in childhood ALL and AML. .MSc Thesis in pediatrics Ain shams university.
- Moore IM, Espy KA, Kaufmann P, et al., (2000):** Cognitive consequences

- and central nervous system injury following treatment for childhood leukemia .Semin Oncol Nurs 16(4): 279-90; discussion 291-9.
- Möricke A, Zimmermann M, Reiter A, et al., (2005):** Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86,90,and 95.Klin Pediatr. Nov-Dec; 217(6):310-20
- Muckenthaler MU, (2008):** Fine tuning of hepcidin expression by positive and negative regulators, Cell Metab. 8(1):1-3.
- Murphy AT, Witcher DR, Luan P, et al.,(2007):** Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry. Blood; 110(3):1048-1054.
- Nathan G and Oski's H, (1998):** Tumors of the hematopoietic system. In Atlas of acute lymphoblastic leukemia. J Clin Oncol; 6:1425
- National Cancer Institute, (2002):** Childhood Acute Lymphoblastic Leukemia(PDQ®): Treatment; Leukemic Cell Characteristic
- Nemeth E. and Ganz T,(2006)...:** Regulation of iron metabolism by hepcidin. Annu Rev Nutr 26 ,323-42.
- Nemeth E, Valore E.V, Territo M, et al.,(2003)..:** Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101 ,2461-3.
- Nemeth E, Rivera S, Gabayan V, et al., (2004a).:**IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113 ,1271-6.
- Nemeth E, Tuttle M.S, Powelson J, et al. ,(2004b).:** Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306 ,2090-3
- Nemeth E, Roetto A, GarozzoG, et al.,(2005):** Hepcidin is decreased in TFR2 hemochromatosis. Blood 105 ,18.
- Nicolas G, Chauvet C, Viatte L, Danan JL,et al., (2002):** The gene encoding

- the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. *J Clin Invest*; 110(7): 1037–1044.
- Nishimoto N, Kanakura Y, Aozasa K, et al.,(2005):** “Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease,” *Blood*, 106 (8)2627–2632.
- Nivison-Smith I, Bradstock KF, Dodds AJ et al.,(2005).** "Haemopoietic stem cell transplantation in Australia and New Zealand, 1992-2001: progress report from the Australasian Bone Marrow Transplant Recipient Registry". *Intern Med J* 35 (1): 18–27.
- Nyvold C, Madsen HO and Ryder LP, (2005):** Percise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. *Blood*, 99(4):1253.
- Origa R, Galanello R, Ganz T, et al.,(2007):**“Liver iron concentrations and urinary hepcidin in β -thalassemia,” *Haematologica*, 92, (5) 583–588.
- Ortega JJ, Madero L, Mart  n G, et al.,: (2005):** Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group. *J Clin Oncol* 23 (30): 7632-40.
- Ozer H, Armitage JO, Bennett CL, et al., (2000):** update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. *J Clin Oncol* 18 (20): 3558-85.
- Papanikolaou G, Tzilianos M, Christakis JI et al., (2005):** Hepcidin in iron overload disorders. *Blood*; 105(10): 4103–4105.
- Park CH, Valore EV, Waring AJ and Ganz T, (2001):** Hepcidin, a urinary antimicrobial peptide synthesized in the liver. *J Biol Chem*. 276:7806–7810 .
- Pavletic SZ, Khouri IF, Haagenson M, et al., (2005).** "Unrelated donor

marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research". J. Clin. Oncol. 23 (24): 5788–94.

Peyssonnaud C, Zinkernagel S, Datta V, et al. ,(2006) : TLR4-dependent hepcidin expression by myeloid cells in response to bacterial pathogens. Blood. 107:3727–3732.

Pigeon C, Ilyin G, Courselaud B, et al. ,(2001): A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is over expressed during iron overload. J Biol Chem 276 ,7811-9.

Pinto, J.P., Ribeiro, S., Pontes, H, et al., (2008): anaemia in patients with chronic kidney Blood 111 , 5727–5733,

Piperno A, Mariani R, Trombini P Det al., (2009): Hepcidin modulation in human diseases: From research to clinic. World J Gastroenterol; 15(5): 538–551.

Pizzo Philip A and Poplack David G, (2006): Textbook of Principles and practice of pediatric oncology, 5th edition.

Pui CH and Crist WM, (2001): Biology and treatment of acute lymphoblastic leukemia. J Pediat; 124:491.

Pui CH and Evans WE, (2004): Acute lymphoblastic leukemia. N Engl J Med 339(9):605-15.

Pui CH and Evans WE, (2006): Treatment of acute lymphoblastic leukemia. N Engl J Med 354(2):166-78.

Pui CH, Boyett JM, Relling MV, et al., (1999): Sex differences in prognosis for children with acute lymphoblastic leukemia.

Pui CH, Qu RP, Chappell RJ, et al.,(2001):Survival after relapse in childhood acute lymphoblastic leukemia. Impact of site and time to first relapse-the Children Cancer Group Experience. Cancer; 82:1389.

- Pui CH, Sandlund JT, Pei D, et al.,(2004):**Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIIB at St Jude Children's Research Hospital. *Blood* 104(9): 2690-6.
- Pullen J, Boyett J, Shuster J, et al.,(2002):**Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group study. *J Clin Oncol* 11(5):839-49.
- Razzouk BI, Estey E, Pounds S, et al.,(2006):** Impact of age on outcome of pediatric acute myeloid leukemia: a report from 2 institutions. *Cancer* 106 (11): 2495-502.
- Reaman GH, Sposto R, Sensel MG, et al., (1999):** Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on consecutive trial of children of the Child Cancer Group. *J Clin Oncol* 17 (2):455-55.
- Reinhardt D, Diekamp S, Langebrake C, et al., (2005):** Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatment. *Leukemia* 19 (8): 1495-6.
- Ries LA, Kosary CL, Hankey BF, et al., (2007):** SEER Cancer Statistics Review,1973-1996. Bethesda, Md: National Cancer Institute, 1999. Also available online. <http://www.seer.cancer.gov/statistics/>
- Rivera GK, Pinkel D, Simone JV, et al., (2003):** Treatment of acute lymphoblastic leukemia.30 years' experience at St. Jude childrens research hospital. *N Engl J Med.* 28;329(18):1289-95.
- Ross JA, Davies SM, Potter JD, et al., (2002):** Epidemiology of childhood leukemia with a focus on infants. *Epidemiol*; 16(2):243..
- Ross JA, Spector LG, Robinson LL et al., (2005):** Epidemiology of leukemia in children with Down syndrome. *Pediatr Blood Cancer.* Jan; 44(1):8-12.

- Rossi E, (2005):** Hepcidin - the Iron Regulatory Hormone. Clin Biochem ReV; 26(3): 47–49.
- Roy C. N, Mak H. H, Akpan I et al.,(2007):** Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation, Blood, 109 (9) 4038–4044.
- Rubnitz JE,(2005):**"acute lymphoblastic leukemia
<http://www.emedicine.com/med/topic2587>.
- Rubnitz JE, Lensing S, Razzouk BI, et al., (2007):** Effect of race on outcome of white and black children with acute myeloid leukemia: the St. Jude experience. Pediatr Blood Cancer 48 (1): 10-5.
- Ruivard M, Laine F, Ganz T, et al., (2009),** “Iron absorption in dysmetabolic iron overload syndrome is decreased and correlates with increased plasma hepcidin,” Journal of Hepatology,50(6) 1219–1225.
- Sasu B. J, Hainu M, Boone T. C, et al., (2008),** “Hepcidin, hepcidin antagonists and methods of use,” US patent no. US2008213277, Amgen Inc.Thousand Oaks, Calif, USA.
- Schimanski L.M, Drakesmith H, Merryweather-Clarke ATet al., (2005):** In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations. Blood 105: 4096-102.
- Schrapppe M, Burger B, Zimmermann M et al.,(2000):** Diagnostic CSF examination in children with ALL: significance of low leukocytic count with blasts on traumatic lumbar puncture. J Clin Oncol; 21(2):184-188.
- Schrapppe M, Reiter A, Ludwig WD, et al.,(2004).** Improved outcome in childhood leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of acute lymphoblastic trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 95 (11): 3310-22.
- Seiter K, (2006) .:** Acute Lymphoblastic Leukemia <http://www.emedicine.com>
- Seiter K, (2010):** Acute Lymphoblastic Leukemia: Differential Diagnosis & Workup.

- Semrin G, Fishman D. S, Bousvaros A, et al.,(2006),** “Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation,” *Inflammatory Bowel Diseases*,. 12(12) :1101–1106.
- Sensel MG, Heerma NA, Sather HN et al.,(2000):**Prognostic impact of trisomy 10,17 and 5 among children with ALL. *Clin Oncol*; 18:1876-1887.
- Shebl S S, El-Fadaly N and Erfan A A,(2004):** outcome of children with acute lymphoblastic leukemia on the basis of cytogenetic study. *Egypt hematology journal*, 29(3).1165-1172.
- Sievers EL, Lange BJ, Alonzo TA, et al., (2003):** Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. *Blood* 101 (9): 3398-406.
- Silverman L, Mclean T, Gelber R, et al.,(2001)b:** Intensified therapy for infants with acute lymphoblastic leukemia, results from the Dana Faber Cancer Institute consortium. *Cancer*, 80(12):2285-95.
- Silverman LB, Gelber RD, Dalton VK, et al., (2001) a:** Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. *Blood* 97 (5):1211-8hospital. *N Engl J Med* 329(18):1289.
- Silverman LB, Gelber RD, Dalton VK, et al., (2001)a:** Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. *Blood* 97 (5):1211-8hospital. *N Engl J Med* 329(18):1289.
- Smith MA, Ries LA, Gurney JG, et al., (2007):** Leukemia. In Ries LA, Smith MA, Gurney JG, et al., eds.: *Cancer incidence and survival among children and adolescents: United State SEER Program 1975-1995*. Bethesda, Md: National Cancer Institute, SEER Program 1999. NIH Pub.No.99-4649.,pp 17-34.

- Sorrer R, Stainer C, Haynes A et al., (2005) :**"Hematopoietic cell transplantation (HCT)- Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT". *Blood* 106 (8): 2912–2919.
- Spivak J,(2002.)** Iron and the anemia of chronic disease. *Oncology* (Williston Park);16 suppl 10:25-33.
- Steven C Auclerc MF, Auvrignon A et al., (2004):** Acute childhood leukemia and environmental exposure to potential sources of benzene and other hydrocarbons; a case control study. *Occup Environ Med.* Sep; 61(9):773-8.
- Swayers CL, (2001) :**Molecular genetics of acute leukemia. *Lancet*; 2001, 349 : 196.
- Swinkels DW and Wetzels JF ,(2008):** Hepcidin: a new tool in the management of anaemia in patients with chronic kidney. *Nephrology Dialysis Transplantation*; 25(5):1093-1098.
- Swinkels DW, Janssen MCH, Bergmans J et al., (2006):** Hereditary hemochromatosis: genetic complexity and new diagnostic approaches. *Clin Chem*; 52:950-68.
- Theurl I, Theurl M, Seifert M, et al., (2008):** Autocrine formation of hepcidin induces iron retention in human monocytes. *Blood*, 111:2392–2399.
- Toyoda Y, Manabe A, Tsuchida M, et al.,(2000):** Six months maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood .*J Clin Oncol*; 18:1508-16.
- Toze CL, Galal A, Barnett MJ, et al., (2005).** "Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease". *Bone Marrow Transplant.* 36 (9): 825–30.
- Trueworthy R, Shuster J, Look T, et al.,(1998):** Ploidy of lymphoblasts is the Strongest Predictor of Treatment Outcome in B-Progenitor Cell

- Acute Lymphoblastic Leukemia of Childhood: A pediatric Oncology Group Study. *J Clin Oncol*; 10(4):606-613.
- Truksa J, Peng H, Lee P and Beutler E, (2007b):** Different regulatory elements are required for response of hepcidin to interleukin-6 and bone morphogenetic proteins 4 and 9. *Br J Haematol* 139 ,138-47.
- Wang R.H, Li C, Zheng Y, et al.,(2005):** A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. *Cell Metab* 2 : 399- 409.
- Weinstein D.A, Roy C.N, Fleming M.D et al.,(2002):** Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. *Blood* 100: 3776- 81.
- Weiss G and Goodnough LT, (2005):** Anemia of chronic disease [review]. *N Engl J Med*. 352:1011–1023.
- Weisser M, Kern W, Rauhut S, et al., (2005):** Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD. *Leukemia*.;19(8):1416-23.
- Wheatley K, Burnett AK, Goldstone AH, et al., (1999):** A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. *Br J Haematol* 107 (1): 69-79.
- Wuchter C, Karawajew L and Rupert V, (2000):.** clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. *Haematologica*. 85:711-21.
- Xie Y, Davies SM, Xiang Y et al., (2003):**Trends in leukemia incidence and survival in the United States(1973-1998).*Cancer* 97(9):2229-35.
- Young M. F, Glahn R. P, Ariza-Nieto M, et al.,(2009):** “Serum hepcidin is significantly associated with iron absorption from food and supplemental

sources in healthy young women,” American Journal of Clinical Nutrition, 89(2): 533–538.

Yu P.B, Hong C.C, Sachidanandan C, et al.,(2008): “Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism,” Nature Chemical Biology, 4(1): 33–41.

Zaki A, (1993): Impact of immunophenotype and karyotype on achievement of complete remission in pediatric acute lymphatic leukemia. MSc. Thesis in Pediatrics. Cairo University.

Zaritsky J, Young B, Wang H.J, et al.,(2009): “Hepcidin-a potential novel biomarker for iron status in chronic kidney disease,” Clinical Journal of the American Society of Nephrology, 4(6): 1051–1056.